Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of ALXN1840 Formulations in Healthy Adults
NCT04610580Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atn-224 in Wilson disease (WD) (6 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Maximum Observed Concentration (Cmax) For Plasma Total Molybdenum (Mo), Maximum Observed Concentration (Cmax) for PUF Mo and 3 more. Started Jan 2021; status: completed.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on NCT04610580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610580.